New lupus drug enters human testing
NCT ID NCT06182969
Summary
This early-stage study is testing a new drug called APG-2575 for people with mild-to-moderate lupus. The main goals are to check if the drug is safe, see how the body processes it, and get a first look at whether it might help control lupus disease activity. About 40 participants will receive either the study drug or a placebo (an inactive substance) to compare the results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital Shanghai Jiaotong University School of Medical
RECRUITINGShanghai, Shanghai Municipality, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.